Sympatholytic agents

Yury Khelemsky, Karina Gritsenko, Christopher Curatolo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Sympatholytic drugs are agents that decrease the activity of the sympathetic nervous system (SNS). This is accomplished via a variety of mechanisms that most commonly include adrenergic receptor blockade (e.g., a and β adrenergic receptor antagonism) as well as specific receptor agonism (i.e., a2 adrenergic receptor agonism) (1). The SNS signal, however, may be blocked in other ways (e.g., peripheral ganglionic blockade) (2).

Original languageEnglish (US)
Title of host publicationPain Medicine
Subtitle of host publicationAn Essential Review
PublisherSpringer International Publishing
Pages193-195
Number of pages3
ISBN (Electronic)9783319431338
ISBN (Print)9783319431314
DOIs
StatePublished - Jan 1 2017

Fingerprint

Sympatholytics
Adrenergic Receptors
Sympathetic Nervous System

Keywords

  • Acute panic performance anxiety
  • Adrenergic receptor antagonism
  • Complex regional pain syndrome
  • Drug interactions
  • Migraine
  • Nightmares
  • Post-traumatic stress disorder
  • Side effects
  • Weaning

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Khelemsky, Y., Gritsenko, K., & Curatolo, C. (2017). Sympatholytic agents. In Pain Medicine: An Essential Review (pp. 193-195). Springer International Publishing. https://doi.org/10.1007/978-3-319-43133-8_54

Sympatholytic agents. / Khelemsky, Yury; Gritsenko, Karina; Curatolo, Christopher.

Pain Medicine: An Essential Review. Springer International Publishing, 2017. p. 193-195.

Research output: Chapter in Book/Report/Conference proceedingChapter

Khelemsky, Y, Gritsenko, K & Curatolo, C 2017, Sympatholytic agents. in Pain Medicine: An Essential Review. Springer International Publishing, pp. 193-195. https://doi.org/10.1007/978-3-319-43133-8_54
Khelemsky Y, Gritsenko K, Curatolo C. Sympatholytic agents. In Pain Medicine: An Essential Review. Springer International Publishing. 2017. p. 193-195 https://doi.org/10.1007/978-3-319-43133-8_54
Khelemsky, Yury ; Gritsenko, Karina ; Curatolo, Christopher. / Sympatholytic agents. Pain Medicine: An Essential Review. Springer International Publishing, 2017. pp. 193-195
@inbook{ab1bc043ff3f4a358faa28bbc278eb71,
title = "Sympatholytic agents",
abstract = "Sympatholytic drugs are agents that decrease the activity of the sympathetic nervous system (SNS). This is accomplished via a variety of mechanisms that most commonly include adrenergic receptor blockade (e.g., a and β adrenergic receptor antagonism) as well as specific receptor agonism (i.e., a2 adrenergic receptor agonism) (1). The SNS signal, however, may be blocked in other ways (e.g., peripheral ganglionic blockade) (2).",
keywords = "Acute panic performance anxiety, Adrenergic receptor antagonism, Complex regional pain syndrome, Drug interactions, Migraine, Nightmares, Post-traumatic stress disorder, Side effects, Weaning",
author = "Yury Khelemsky and Karina Gritsenko and Christopher Curatolo",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43133-8_54",
language = "English (US)",
isbn = "9783319431314",
pages = "193--195",
booktitle = "Pain Medicine",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Sympatholytic agents

AU - Khelemsky, Yury

AU - Gritsenko, Karina

AU - Curatolo, Christopher

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Sympatholytic drugs are agents that decrease the activity of the sympathetic nervous system (SNS). This is accomplished via a variety of mechanisms that most commonly include adrenergic receptor blockade (e.g., a and β adrenergic receptor antagonism) as well as specific receptor agonism (i.e., a2 adrenergic receptor agonism) (1). The SNS signal, however, may be blocked in other ways (e.g., peripheral ganglionic blockade) (2).

AB - Sympatholytic drugs are agents that decrease the activity of the sympathetic nervous system (SNS). This is accomplished via a variety of mechanisms that most commonly include adrenergic receptor blockade (e.g., a and β adrenergic receptor antagonism) as well as specific receptor agonism (i.e., a2 adrenergic receptor agonism) (1). The SNS signal, however, may be blocked in other ways (e.g., peripheral ganglionic blockade) (2).

KW - Acute panic performance anxiety

KW - Adrenergic receptor antagonism

KW - Complex regional pain syndrome

KW - Drug interactions

KW - Migraine

KW - Nightmares

KW - Post-traumatic stress disorder

KW - Side effects

KW - Weaning

UR - http://www.scopus.com/inward/record.url?scp=85032896463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032896463&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43133-8_54

DO - 10.1007/978-3-319-43133-8_54

M3 - Chapter

AN - SCOPUS:85032896463

SN - 9783319431314

SP - 193

EP - 195

BT - Pain Medicine

PB - Springer International Publishing

ER -